Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial

Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial

Abstract Background The pivotal ASPECT-NP trial showed ceftolozane/tazobactam was non-inferior to meropenem for the treatment of ventilated hospital-acquired/ventilator-associated bacterial pneumonia (vHABP/VABP). Here, we evaluated treatment outcomes by degree of respiratory or cardiovascular dysfu...

Full description

Bibliographic Details
Main Authors: Ignacio Martin-Loeches, Andrew F. Shorr, Richard G. Wunderink, Marin H. Kollef, Jean-François Timsit, Brian Yu, Jennifer A. Huntington, Erin Jensen, Christopher J. Bruno
Format: Article
Language:English
Published: SpringerOpen 2023-02-01
Series:Annals of Intensive Care
Subjects:
ASPECT-NP
Gram-negative
Nosocomial
Pneumonia
Pseudomonas
Shock
Online Access:https://doi.org/10.1186/s13613-022-01084-8

Internet

https://doi.org/10.1186/s13613-022-01084-8

Similar Items